[1]

Newman DJ, Cragg GM. 2020. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products 83:770−803

doi: 10.1021/acs.jnatprod.9b01285
[2]

Wang Z, Zhang T, Wang B, Li S. 2025. TCM network pharmacology: new perspective integrating network target with artificial intelligence and multi-modal multi-omics technologies. Chinese Journal of Natural Medicines 23:1425−1434

doi: 10.1016/S1875-5364(25)60986-1
[3]

Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. 2021. Natural products in drug discovery: advances and opportunities. Nature Reviews Drug Discovery 20:200−216

doi: 10.1038/s41573-020-00114-z
[4]

Zhu Y, Ouyang Z, Du H, Wang M, Wang J, et al. 2022. New opportunities and challenges of natural products research: when target identification meets single-cell multiomics. Acta Pharmaceutica Sinica B 12:4011−4039

doi: 10.1016/j.apsb.2022.08.022
[5]

Wang S, Zhang Y, Yu R, Chai Y, Liu R, et al. 2024. Labeled and label-free target identifications of natural products. Journal of Medicinal Chemistry 67:17980−17996

doi: 10.1021/acs.jmedchem.4c01576
[6]

Jiang X, Shon K, Li X, Cui G, Wu Y, et al. 2024. Recent advances in identifying protein targets of bioactive natural products. Heliyon 10:e33917

doi: 10.1016/j.heliyon.2024.e33917
[7]

Zhang Y, Zhang J, Li M, Qiao Y, Wang W, et al. 2023. Target discovery of bioactive natural products with native-compound-coupled CNBr-activated Sepharose 4B beads (NCCB): applications, mechanisms and outlooks. Bioorganic & Medicinal Chemistry 96:117483

doi: 10.1016/j.bmc.2023.117483
[8]

Song J. 2025. Applications of the cellular thermal shift assay to drug discovery in natural products: a review. International Journal of Molecular Sciences 26:3940

doi: 10.3390/ijms26093940
[9]

Zhen X, Liu J, Ren Y. 2025. Recent advances in proteomic strategies for target identification of traditional Chinese medicine. Journal of Pharmaceutical Analysis 00:101516

doi: 10.1016/j.jpha.2025.101516
[10]

Gao Y, Ma M, Li W, Lei X. 2024. Chemoproteomics, a broad avenue to target deconvolution. Advanced Science 11:e2305608

doi: 10.1002/advs.202305608
[11]

Liu TT, Zeng KW. 2025. Recent advances in target identification technology of natural products. Pharmacology & Therapeutics 269:108833

doi: 10.1016/j.pharmthera.2025.108833
[12]

Harding MW, Galat A, Uehling DE, Schreiber SL. 1989. A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase. Nature 341:758−760

doi: 10.1038/341758a0
[13]

Sato SI, Murata A, Orihara T, Shirakawa T, Suenaga K, et al. 2011. Marine natural product aurilide activates the OPA1-mediated apoptosis by binding to prohibitin. Chemistry & Biology 18:131−139

doi: 10.1016/j.chembiol.2010.10.017
[14]

Li J, Casteels T, Frogne T, Ingvorsen C, Honoré C, et al. 2017. Artemisinins target GABAA receptor signaling and impair α cell identity. Cell 168:86−100. e15

doi: 10.1016/j.cell.2016.11.010
[15]

Zeng KW, Wang JK, Wang LC, Guo Q, Liu TT, et al. 2021. Small molecule induces mitochondrial fusion for neuroprotection via targeting CK2 without affecting its conventional kinase activity. Signal Transduction and Targeted Therapy 6:71

doi: 10.1038/s41392-020-00447-6
[16]

Niphakis MJ, Cravatt BF. 2024. Ligand discovery by activity-based protein profiling. Cell Chemical Biology 31:1636−1651

doi: 10.1016/j.chembiol.2024.08.006
[17]

Liu Y, Patricelli MP, Cravatt BF. 1999. Activity-based protein profiling: the serine hydrolases. Proceedings of the National Academy of Sciences of the United States of America 96:14694−14699

doi: 10.1073/pnas.96.26.14694
[18]

Porta EOJ, Steel PG. 2023. Activity-based protein profiling: a graphical review. Current Research in Pharmacology and Drug Discovery 5:100164

doi: 10.1016/j.crphar.2023.100164
[19]

Zhou YF, Zhang L, Niu ZL, Wang ZA. 2025. Targeting the reactive proteome: recent advances in activity-based protein profiling and probe design. Biomolecules 15:1699

doi: 10.3390/biom15121699
[20]

Wang Q, Du T, Zhang Z, Zhang Q, Zhang J, et al. 2024. Target fishing and mechanistic insights of the natural anticancer drug candidate chlorogenic acid. Acta Pharmaceutica Sinica B 14:4431−4442

doi: 10.1016/j.apsb.2024.07.005
[21]

He X, Wang C, Zhang Q, Yang T, Guo Q, et al. 2025. Identifying ENO1 as a protein target of chlorogenic acid to inhibit cellular senescence and prevent skin photoaging in mice. Aging Cell 24:e14433

doi: 10.1111/acel.14433
[22]

Nie HJ, Fu YJ, Long S, Wang JY, Zhao WS, et al. 2025. Chemoproteomics reveals proteome-wide covalent and non-covalent targets of with afer in A. Acta Pharmacologica Sinica 46:1782−1793

doi: 10.1038/s41401-024-01468-5
[23]

He X, Wang C, Zhang R, Wang Y, Zhang Y, et al. 2026. Parthenolide ameliorates inflammation in sepsis via covalently targeting Trim33 and inhibiting NF-κB pathway. Phytomedicine 153:157862

doi: 10.1016/j.phymed.2026.157862
[24]

Yuan S, Zhou YF, Ma B, Liu Y, Zhang J, et al. 2026. Chemoproteomics identifies STAT3 as a key target of baicalin in ameliorating liver fibrosis. National Science Review 13:nwag093

doi: 10.1093/nsr/nwag093
[25]

Tu Y, Tan L, Tao H, Li Y, Liu H. 2023. CETSA and thermal proteome profiling strategies for target identification and drug discovery of natural products. Phytomedicine 116:154862

doi: 10.1016/j.phymed.2023.154862
[26]

Zhang L, Wang Y, Zheng C, Zhou Z, Chen Z. 2024. Cellular thermal shift assay: an approach to identify and assess protein target engagement. Expert Review of Proteomics 21:387−400

doi: 10.1080/14789450.2024.2406785
[27]

Molina DM, Jafari R, Ignatushchenko M, Seki T, Larsson EA, et al. 2013. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341:84−87

doi: 10.1126/science.1233606
[28]

Savitski MM, Reinhard FBM, Franken H, Werner T, Savitski MF, et al. 2014. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346:1255784

doi: 10.1126/science.1255784
[29]

Dziekan JM, Yu H, Chen D, Dai L, Wirjanata G, et al. 2019. Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay. Science Translational Medicine 11:eaau3174

doi: 10.1126/scitranslmed.aau3174
[30]

Kirsch VC, Orgler C, Braig S, Jeremias I, Auerbach D, et al. 2020. The cytotoxic natural product Vioprolide A targets nucleolar protein 14, which is essential for ribosome biogenesis. Angewandte Chemie International Edition 59:1595−1600

doi: 10.1002/anie.201911158
[31]

Zhang XW, Li L, Liao M, Liu D, Rehman A, et al. 2024. Thermal proteome profiling strategy identifies CNPY3 as a cellular target of gambogic acid for inducing prostate cancer pyroptosis. Journal of Medicinal Chemistry 67:10005−10011

doi: 10.1021/acs.jmedchem.4c00140
[32]

Ren YS, Li HL, Piao XH, Yang ZY, Wang SM, et al. 2021. Drug affinity responsive target stability (DARTS) accelerated small molecules target discovery: principles and application. Biochemical Pharmacology 194:114798

doi: 10.1016/j.bcp.2021.114798
[33]

Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, et al. 2009. Target identification using drug affinity responsive target stability (DARTS). Proceedings of the National Academy of Sciences of the United States of America 106:21984−21989

doi: 10.1073/pnas.0910040106
[34]

Xing Z, Cai X, He T, Li P, He J, et al. 2025. VCP's nuclear journey: initiated by interacting with KPNB1 to repair DNA damage. Proceedings of the National Academy of Sciences of the United States of America 122:e2416045122

doi: 10.1073/pnas.2416045122
[35]

Feng L, Wang X, Guo X, Shi L, Su S, et al. 2024. Identification of novel target DCTPP1 for colorectal cancer therapy with the natural small-molecule inhibitors regulating metabolic reprogramming. Angewandte Chemie International Edition 63:e202402543

doi: 10.1002/anie.202402543
[36]

Yuan J, Tao Y, Wang M, Chen Y, Han X, et al. 2026. Astragaloside II, a natural saponin, facilitates remyelination in demyelination neurological diseases via p75NTR receptor mediated β-catenin/Id2/MBP signaling axis in oligodendrocyte precursor cells. Journal of Advanced Research 80:577−591

doi: 10.1016/j.jare.2025.04.028
[37]

Stanton BZ, Chory EJ, Crabtree GR. 2018. Chemically induced proximity in biology and medicine. Science 359:eaao5902

doi: 10.1126/science.aao5902
[38]

Crabtree GR, Schreiber SL. 1996. Three-part inventions: intracellular signaling and induced proximity. Trends in Biochemical Sciences 21:418−422

doi: 10.1016/S0968-0004(96)20027-1
[39]

Liu X, Ciulli A. 2023. Proximity-based modalities for biology and medicine. ACS Central Science 9:1269−1284

doi: 10.1021/acscentsci.3c00395
[40]

Dikic I, Mayor-Ruiz C, Winter GE, Koch K, Ciulli A, et al. 2025. Opportunities in proximity modulation: bridging academia and industry. Molecular Cell 85:3012−3022

doi: 10.1016/j.molcel.2025.07.018
[41]

Raina K, Forbes CD, Stronk R, Rappi JP Jr, Eastman KJ, et al. 2024. Regulated induced proximity targeting chimeras—RIPTACs—a heterobifunctional small molecule strategy for cancer selective therapies. Cell Chemical Biology 31:1490−1502.e42

doi: 10.1016/j.chembiol.2024.07.005
[42]

Krone MW, Crews CM. 2025. Next steps for targeted protein degradation. Cell Chemical Biology 32:219−226

doi: 10.1016/j.chembiol.2024.10.004
[43]

Békés M, Langley DR, Crews CM. 2022. PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery 21:181−200

doi: 10.1038/s41573-021-00371-6
[44]

Pike A, Lee ECY, Michaelides IN, Schade M, Sharma A, et al. 2026. Lessons learned in linking PROTACs from discovery to the clinic. Nature Reviews Chemistry 10:117−132

doi: 10.1038/s41570-025-00784-6
[45]

Vetma V, O'Connor S, Ciulli A. 2025. Development of PROTAC degrader drugs for cancer. Annual Review of Cancer Biology 9:119−140

doi: 10.1146/annurev-cancerbio-061824-105806
[46]

Zhu B, Wu Z, Shou Y, Zhao K, Lu Q, et al. 2025. Harnessing the power of natural products for targeted protein degradation. Medicinal Research Reviews 45:1466−1514

doi: 10.1002/med.22113
[47]

Li Y, Jia Y, Wang X, Shang H, Tian Y. 2023. Protein-targeted degradation agents based on natural products. Pharmaceuticals 16:46

doi: 10.3390/ph16010046
[48]

Liu Y, Liang J, Zhu R, Yang Y, Wang Y, et al. 2024. Application of PROTACs in target identification and target validation. Acta Materia Medica 3:72−87

doi: 10.15212/amm-2024-0010
[49]

Spitz ML, Kashkush A, Benhamou RI. 2025. Advancing target validation with PROTAC technology. Expert Opinion on Drug Discovery 20:551−563

doi: 10.1080/17460441.2025.2490248
[50]

Ni Z, Shi Y, Liu Q, Wang L, Sun X, et al. 2024. Degradation-based protein profiling: a case study of celastrol. Advanced Science 11:e2308186

doi: 10.1002/advs.202308186
[51]

Wu Y, Yang Y, Wang W, Sun D, Liang J, et al. 2022. PROTAC technology as a novel tool to identify the target of lathyrane diterpenoids. Acta Pharmaceutica Sinica B 12:4262−4265

doi: 10.1016/j.apsb.2022.07.007
[52]

Li Y, Zeng ZW, Chen D, Gu ZC, Yan WL, et al. 2023. Facilitated drug repurposing with artemisinin-derived PROTACs: unveiling PCLAF as a therapeutic target. Journal of Medicinal Chemistry 66:11335−11350

doi: 10.1021/acs.jmedchem.3c00824
[53]

Chen S, Bi K, Liang H, Wu Z, Huang M, et al. 2024. PROTAC derivatization of natural products for target identification and drug discovery: design of evodiamine-based PROTACs as novel REXO4 degraders. Journal of Advanced Research 63:219−230

doi: 10.1016/j.jare.2023.10.014
[54]

Yu H, Chen Y, Wu M, Wang W, Qiu J, et al. 2026. Stability and degradation-based proteome profiling reveals cannabidiol as a promising CDC123-eIF2γ inhibitor for colorectal cancer therapy. Journal of the American Chemical Society 148:3712−3722

doi: 10.1021/jacs.5c20040
[55]

Nguyen T, Le H, Quinn TP, Nguyen T, Le TD, et al. 2021. GraphDTA: predicting drug-target binding affinity with graph neural networks. Bioinformatics 37:1140−1147

doi: 10.1093/bioinformatics/btaa921
[56]

Wang Y, Sui Y, Yao J, Jiang H, Tian Q, et al. 2024. Herb-CMap: a multimodal fusion framework for deciphering the mechanisms of action in traditional Chinese medicine using Suhuang antitussive capsule as a case study. Briefings in Bioinformatics 25:bbae362

doi: 10.1093/bib/bbae362
[57]

Li F, Hu Q, Zhang X, Sun R, Liu Z, et al. 2022. DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs. Nature Communications 13:7133

doi: 10.1038/s41467-022-34807-3
[58]

Zhang W, Roy Burman SS, Chen J, Donovan KA, Cao Y, et al. 2022. Machine learning modeling of protein-intrinsic features predicts tractability of targeted protein degradation. Genomics Proteomics Bioinformatics 20:882−898

doi: 10.1016/j.gpb.2022.11.008
[59]

Xie L, Xie L. 2023. Elucidation of genome-wide understudied proteins targeted by PROTAC-induced degradation using interpretable machine learning. PLoS Computational Biology 19:e1010974

doi: 10.1371/journal.pcbi.1010974
[60]

Liu J, Roy MJ, Isbel L, Li F. 2025. Accurate PROTAC-targeted degradation prediction with DegradeMaster. Bioinformatics 41:i342−i351

doi: 10.1093/bioinformatics/btaf191
[61]

Zaidman D, Prilusky J, London N. 2020. PRosettaC: rosetta based modeling of PROTAC mediated ternary complexes. Journal of Chemical Information and Modeling 60:4894−4903

doi: 10.1021/acs.jcim.0c00589
[62]

Abramson J, Adler J, Dunger J, Evans R, Green T, et al. 2024. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630:493−500

doi: 10.1038/s41586-024-07487-w
[63]

Xue F, Zhang M, Li S, Gao X, Wohlschlegel JA, et al. 2025. SE(3)-equivariant ternary complex prediction towards target protein degradation. Nature Communications 16:5514

doi: 10.1038/s41467-025-61272-5